提取
有越来越多的证据表明阻塞性睡眠呼吸暂停(OSA)与癌症之间存在潜在的联系,但这些证据存在争议[1-10]。由于样本量有限,以及OSA表型或恶性肿瘤类型(所有类型[1-4]或位点特异性[6-8])的定性较差,现有的研究得出了相互矛盾的结论。已经有几个假说阐明了为什么OSA会发生癌变,包括年龄增大、睡眠不足[11,12]和伴随肥胖的[13]。间歇性缺氧和睡眠碎片可能起重要作用通过改建血管生成,交感神经流出,或免疫功能和肿瘤微环境[11,12]的调制。在OSA和癌症发病率之间的关联性别特异性差异已经研究甚少。
抽象
在欧洲睡眠呼吸暂停数据库(ESADA)的横截面的分析,癌症患病率为女性患有OSA和夜间缺氧更高,但不是在男性。还需要进一步研究,以评估的性别,OSA和癌症的发病率因果关系。http://bit.ly/2YuxyZA
确认
作者感谢(当前和过去)的ESADA研究组的所有合作者:P. Steiropoulos,休眠单元,Pneumonology的部门,色雷斯,亚历山德鲁波利斯,希腊德谟克利特大学;J. Verbraecken,多学科的睡眠障碍中心,安特卫普大学医院和安特卫普,比利时安特卫普大学;E. Petiet,多学科的睡眠障碍中心,安特卫普大学医院和安特卫普,比利时安特卫普大学;G. Trakada,胸腔内科,国家和雅典,雅典,希腊Kapodistrian大学;J.M.蒙特塞拉特,医院门诊我省巴塞罗那,巴塞罗那,巴塞罗那IDIBAPS和CIBERes,马德里,西班牙;I. Fietze,Schlafmedizinisches中央区,慈善 - 医药柏林,德国的大学;T. Penzel,Schlafmedizinisches中央区,慈善 - 医药柏林,德国的大学;O. Ludka,心内科,大学医院布尔诺和国际临床研究中心,圣安大学医院,捷克共和国布尔诺的部门;D. Rodenstein,15-9 Universitaires圣 - 吕克,布鲁塞尔,比利时;J.F.马萨,医院圣佩德罗德阿Alcΰntara,Caeceres和CIBERes,马德里,西班牙; I. Bouloukaki, Sleep Disorders Unit, Dept of Respiratory Medicine, Medical School, University of Crete, Greece; S. Schiza, Sleep Disorders Unit, Dept of Respiratory Medicine, Medical School, University of Crete, Greece; B. Kent, Guy's and St Thomas’ NHS Foundation Trust, Guy's Hospital, London, UK; W.T. McNicholas, Dept of Respiratory Medicine, St. Vincent΄s University Hospital, Dublin, Ireland; S. Ryan, Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland; R.L. Riha, Dept of Sleep Medicine, Royal Infirmary Edinburgh, UK; J.A. Kvamme, Sleep Laboratory, ENT Dept, Forde Central Hospital, Forde, Norway; R. Schulz, Sleep Disorders Centre, University of Giessen, Lung Centre, Giessen, Germany; L. Grote, Sleep Disorders Center, Pulmonary Dept, Sahlgrenska University Hospital, and Center of Sleep and Wake Disorders, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; J. Hedner, Sleep Disorders Center, Pulmonary Dept, Sahlgrenska University Hospital, and Center of Sleep and Wake Disorders, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; J-L. Pepin, University Grenoble Alpes, INSERM HP2 (U1042) and Grenoble University Hospital, Grenoble, France; P. Levy, University Grenoble Alpes, INSERM HP2 (U1042) and Grenoble University Hospital, Grenoble, France; L. Lavie, Centre for Sleep Medicine, Technion Institute of Technology, Haifa, Israel; P. Lavie, Centre for Sleep Medicine, Technion Institute of Technology, Haifa, Israel; H. Hein, Sleep Disorders Center, St. Adolf Stift, Reinbeck, Germany; O.K. Basoglu, Dept of Chest Diseases, Ege University, Izmir, Turkey; M.S. Tasbakan, Dept of Chest Diseases, Ege University, Izmir, Turkey; G. Varoneckas, Institute Psychophysiology and Rehabilitation, Palanga, Lithuania; P. Joppa, Dept of Respiratory Medicine and Tuberculosis, Faculty of Medicine, P.J. Safarik University and L. Pasteur University Hospital, Kosice, Slovakia; R. Tkacova, Dept of Respiratory Medicine and Tuberculosis, Faculty of Medicine, P.J. Safarik University and L. Pasteur University Hospital, Kosice, Slovakia; R. Staats, Dept of Respiratory Medicine, Hospital de Santa Maria, Lisbon, Portugal; F. Barbe, Servei Pneumologia Hospital Arnau de Vilanova and Hospital Santa Maria, Lleida, and CIBERes, Madrid, Spain; C. Lombardi, Istituto Auxologico Italiano, IRCCS, Dept of Cardiovascular, Neural and Metabolic Sciences, St Luke Hospital, Milan and Dept of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; G. Parati, Istituto Auxologico Italiano, IRCCS, Dept of Cardiovascular, Neural and Metabolic Sciences, St Luke Hospital, Milan and Dept of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; M. Drummond, Pulmonology Dept, Hospital São João, Medicine Faculty of Porto University, Porto, Portugal; M. van Zeller, Pulmonology Dept, Hospital São João, Medicine Faculty of Porto University, Porto, Portugal; M.R. Bonsignore, Biomedical Dept of Internal and Specialistic Medicine (DiBiMIS), Section of Pneumology, University of Palermo, and CNR Institute of Biomedicine and Molecular Immunology, Palermo, Italy; O. Marrone, CNR Institute of Biomedicine and Molecular Immunology, Palermo, Italy; P. Escourrou, Service dΙxplorations Fonctionnelles Multidisciplinaires Hospital Antoine Beclere, Clamart, France; G. Roisman, Unitι de Mιdecine du Sommeil, Hopital Antoine-Beclere, Clamart, France; M. Pretl, Centre for Sleep and Waking Disorders, Dept of Neurology, First Faculty of Medicine, Charles University, Prague, and Inspamed, Neurology and Sleep Laboratory, Prague, Czech Republic; A. Vitols, Institute of Cardiology, University of Latvia, Riga, Latvia; Z. Dogas, Sleep Medicine Center, Dept of Neuroscience, University of Split School of Medicine, Split, Croatia; T. Galic, Sleep Medicine Center, Dept of Neuroscience, University of Split School of Medicine, Split, Croatia; A. Pataka, Respiratory Failure Unit, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Greece; U. Anttalainen, Division of Medicine, Dept of Pulmonary Diseases, Turku University Hospital and Sleep Research Centre, Dept of Pulmonary Diseases and Clinical Allergology, University of Turku, Finland; T. Saaresranta, Division of Medicine, Dept of Pulmonary Diseases, Turku University Hospital and Sleep Research Centre, Dept of Pulmonary Diseases and Clinical Allergology, University of Turku, Finland; P. Sliwinski, 2nd Dept of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; R. Plywaczewski, 2nd Dept of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; P. Bielicki, Dept of Internal Medicine, Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland.
脚注
利益冲突:答:Pataka没有什么要披露的。
利益冲突:M.R.邦西格诺有没有透露。
利益冲突:s·瑞安没有什么要披露的。
利益冲突:R.L.里哈有没有透露。
J-L:利益冲突。佩潘报告补助和研究经费从液化空气集团基金会,Agiradom,阿斯利康,费舍尔和派克,Mutualia,飞利浦,瑞思迈和Vitalaire,从Agiradom,阿斯利康,勃林格殷格翰,爵士药业,夜平衡,飞利浦,瑞思迈和Sefam个人费用。
利益冲突:S. Schiza有没有透露。
利益冲突:O.K. Basoglu没有什么要披露的。
利益冲突:P. Sliwinski有没有透露。
利益冲突:O. Ludka没有什么要披露的。
利益冲突:P. Steiropoulos有没有透露。
利益冲突:安泰莱宁没有任何需要披露的信息。
利益冲突:W.T. McNicholas没有什么要披露的。
利益冲突:J. Hedner报告了来自ResMed基金会、Philips呼吸器和欧洲呼吸协会的资助,用于启动和开展这项研究。188bet官网地址
利益冲突:L.格罗特在研究进行期间,从报告瑞思迈基金会和伟康基金会,补助金;个人费用从瑞思迈,飞利浦和伊塔马尔,从瑞思迈,其他(设备)从伊塔马尔补助讲课,提交作品之外;此外,L格罗特有睡眠呼吸暂停的治疗申请专利。
支持声明:ESADA网络已获得欧盟成本行动B26的支持,目前是由欧洲呼吸协会资助的临床研究合作项目。188bet官网地址此外,ESADA研究小组还获得了ResMed和Philips呼吸器基金会的无限制种子拨款,用于在2007年和2011年建立该数据库。ESADA与拜耳公司有持续的合作。欧洲睡眠研究协会和欧洲呼吸协会为ESADA的合作者提供了通信、会议和数据演示方面的非财务支持。188bet官网地址
- 收到2018年10月17日。
- 接受2019年3月5日。
- 版权所有©ERS 2019
个人
使用您的用户名和密码登录
图书馆用户
通过你的机构登录
购买访问
联系我们
如果您对ERS出版物的网站有任何疑问,请联系journals@ersnet.org